Trial Profile

Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD45-chimeric-antigen-receptor-T-cell-therapy-Kite-Pharma (Primary)
Indications Anaplastic large cell lymphoma; B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Immunoblastic lymphadenopathy; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Adverse reactions

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com